Hims & Hers Health, Inc. is rated a Buy with strong subscriber growth and rising revenue per subscriber. Learn more about ...
The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...
Stocktwits on MSN
Hims & Hers CEO bets on personalized healthcare and AI in 2026 — Wall Street braces for a costly year
Dudum said individuals are taking greater control of care through DTC access, preventive health, and wider use of AI. ・BofA ...
Zacks Investment Research on MSN
Hims & Hers plunges 39.2% in 3 months: Time to hold the stock or sell?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. The San Francisco, CA-based ...
Investing.com -- Hims & Hers Health (NYSE:HIMS) stock fell 4% Friday after Amazon (NASDAQ:AMZN) Pharmacy announced it would ...
Hims & Hers trades at FWD EV/Sales of 3.45x and FWD EV/EBITDA of 25.85x, with FY2030 targets implying further upside for ...
A coalition of telehealth providers from Amazon and Hims & Hers to hospital systems is working to extend pandemic-era waivers ...
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo ...
A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback